These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10370787)

  • 1. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
    van Moorsel CJ; Kroep JR; Pinedo HM; Veerman G; Voorn DA; Postmus PE; Vermorken JB; van Groeningen CJ; van der Vijgh WJ; Peters GJ
    Ann Oncol; 1999 Apr; 10(4):441-8. PubMed ID: 10370787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
    van Moorsel CJ; Pinedo HM; Smid K; Comijn EM; Voorn DA; Veerman G; Lakerveld B; Van der Vijgh WJ; Giaccone G; Postmus PE; Peters GJ
    Eur J Cancer; 2000 Dec; 36(18):2420-9. PubMed ID: 11094319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
    Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
    Rademaker-Lakhai JM; Crul M; Pluim D; Sparidans RW; Baas P; Beijnen JH; van Zandwijk N; Schellens JH
    Anticancer Drugs; 2005 Oct; 16(9):1029-36. PubMed ID: 16162981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
    Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
    Kroep JR; Giaccone G; Voorn DA; Smit EF; Beijnen JH; Rosing H; van Moorsel CJ; van Groeningen CJ; Postmus PE; Pinedo HM; Peters GJ
    J Clin Oncol; 1999 Jul; 17(7):2190-7. PubMed ID: 10561275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
    Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine-cisplatin: a schedule finding study.
    Kroep JR; Peters GJ; van Moorsel CJ; Catik A; Vermorken JB; Pinedo HM; van Groeningen CJ
    Ann Oncol; 1999 Dec; 10(12):1503-10. PubMed ID: 10643544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
    Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
    J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
    Fan Y; Lin NM; Ma SL; Luo LH; Fang L; Huang ZY; Yu HF; Wu FQ
    Acta Pharmacol Sin; 2010 Jun; 31(6):746-52. PubMed ID: 20523345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.
    Caffo O; Fallani S; Marangon E; Nobili S; Cassetta MI; Murgia V; Sala F; Novelli A; Mini E; Zucchetti M; Galligioni E
    Cancer Chemother Pharmacol; 2010 May; 65(6):1197-202. PubMed ID: 20140616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
    Sabbatini P; Aghajanian C; Leitao M; Venkatraman E; Anderson S; Dupont J; Dizon D; O'Flaherty C; Bloss J; Chi D; Spriggs D
    Clin Cancer Res; 2004 May; 10(9):2962-7. PubMed ID: 15131031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
    Schultheis B; Kummer G; Zeth M; Brendel E; Xia C; Kornacker M; Strumberg D
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):333-9. PubMed ID: 21735354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
    Ceresa C; Giovannetti E; Voortman J; Laan AC; Honeywell R; Giaccone G; Peters GJ
    Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
    Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
    Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
    Crul M; Schoemaker NE; Pluim D; Maliepaard M; Underberg RW; Schot M; Sparidans RW; Baas P; Beijnen JH; Van Zandwijk N; Schellens JH
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3526-33. PubMed ID: 14506138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
    Grunewald R; Kantarjian H; Keating MJ; Abbruzzese J; Tarassoff P; Plunkett W
    Cancer Res; 1990 Nov; 50(21):6823-6. PubMed ID: 2208147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
    Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
    Rajan A; Carter CA; Kelly RJ; Gutierrez M; Kummar S; Szabo E; Yancey MA; Ji J; Mannargudi B; Woo S; Spencer S; Figg WD; Giaccone G
    Clin Cancer Res; 2012 Apr; 18(8):2344-51. PubMed ID: 22371451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.